# Diabetes Research Hub — Iteration Report

**Date:** 2026-06-07 (Sunday)
**Mode:** Automated scheduled run
**Queue items processed:** 4 (plus every-run sweeps)

---

## 1. Credibility sweep — CLEAN ✅

Grepped all `Analysis/Scripts/*.py` for the doctrine's red flags:

- **Fabricated PMIDs (>42,000,000):** none found.
- **"zero SAEs" / "zero rejection":** none found.
- **"achieves" / "curative" / "cure" in preclinical context:** all hits legitimate —
  category labels (e.g. "T1D Cure & Cell Therapy"), PubMed search-query strings,
  the `verify_before_deploy.py` detection patterns themselves, and properly-caveated
  BRONZE preclinical claims (e.g. Stanford hybrid-immune mouse study explicitly tagged
  mice/human-translation-uncertain). No fixes required.

## 2. Path validation — 5 paths VALIDATED ✅

Validated the next unvalidated batch via external evidence (`validated_paths` now 36):

| Path | Rating | Key external evidence |
|------|--------|------------------------|
| dapagliflozin → inflammation | VALIDATED | Cardiovasc Diabetol 2024 (PMC11161924, clinical systemic-inflammation reduction); Nat Commun 2020 (PMID 32358544, ketone/NLRP3 mechanism); Birnbaum 2017 cardiomyopathy mice |
| empagliflozin → inflammation | VALIDATED | PMID 32358544 (30-day macrophage NLRP3/IL-1β, T2D high-CV-risk); PMID 38172306 (vascular calcification); PMID 41680826 (2025 timing-dependent RCT, n=66) |
| NF_kB → inflammation | VALIDATED (high) | Front Pharmacol 2017 (PMC5681994); Cell Metab 2011 review — canonical master regulator of pro-inflammatory transcription + NLRP3 priming |
| oxidative_stress → cardiovascular | VALIDATED (high) | Circ Res 2010 (Giacco & Brownlee); Antioxidants 2025 (PMC11759781); Front Cardiovasc Med 2021 |
| dorzagliatin → T2D | VALIDATED | Nat Med 2022 DAWN (add-on, HbA1c −1.02%); SEED (mono, −1.07% vs −0.50% placebo); review PMID 38783768 |

Notable caveats recorded in state: SGLT2i NLRP3 human data are systemic-marker level (not
tissue NLRP3); antioxidant-supplementation RCTs have not shown CV outcome benefit despite the
validated mechanism; dorzagliatin durability/CV-outcome data still limited.

## 3. Gap 1 audit — Gene Therapy for LADA (SILVER) — no change

Interim queue-triggered check (8 days after the 2026-05-29 monthly audit). Search returned only
T1D-framed CRISPR programs, the Front Endocrinol 2022 LADA β-cell-protection review, and the
ongoing GAD-Alum + oral vitamin D LADA pilot (PMC9339700, immunotherapy — not gene therapy).
**Zero LADA-specific gene-therapy trials registered.** Retain SILVER; not a promotion candidate.
Next monthly audit due **2026-06-29**.

## 4. Pipeline rebuild — all 41 [OK] ✅

`run_quality_improvements.py` completed all 41 build/verify steps successfully.

## 5. Notes & blockers

- Today is Sunday → weekly PubMed sweep (Monday-only) skipped.
- All 285 papers remain VETTED (272) / FLAGGED (13); no unvetted papers in backlog.
- **git push still BLOCKED:** sandbox HTTPS remote has no GitHub credential helper.
  Local commits succeed; user must run `git push origin main` from the host terminal.

## Queue after this run

Top actionable next: continue path validation (next batch: oxidative_stress→inflammation,
NLRP3→cardiovascular, metformin→inflammation, GLP1→cardiovascular, SGLT2i→nephropathy);
Abata ABA-201 PubMed check (due 2026-07-02); monthly gap audits clustered late-June / early-July.
